Multiple Myeloma

Progression-Free Survival Extended With PANEX Protocol in R/R Multiple Myeloma

Progression-Free Survival Extended With PANEX Protocol in R/R Multiple Myeloma

By

This treatment-expansion study evaluated the tolerability and safety of the PANEX (panobinostat plus bortezomib with dexamethasone) protocol in heavily treated patients with R/R multiple myeloma.

Long-term Carfilzomib May Be Safe, Effective In Relapsed Multiple Myeloma

Long-term Carfilzomib May Be Safe, Effective In Relapsed Multiple Myeloma

By

In a post-hoc analysis of the ASPIRE trial results, in which carfilzomib was discontinued due to a lack of long-term safety data, researchers present the safety and efficacy findings of KRd vs Rd for relapsed multiple myeloma at 18 months from randomization.

Ciprofloxacin Plus Doxycycline Reduces Infection Rate in Multiple Myeloma Post-ASCT

Ciprofloxacin Plus Doxycycline Reduces Infection Rate in Multiple Myeloma Post-ASCT

By

A health outcomes analysis of 419 patients with multiple myeloma sought to determine if cipro-doxy was more effective than cipro alone in reducing the incidence of neutropenic fever and infections, both significant causes of morbidity and death for these patients.

Bisphosphonate Therapy Underutilized in Multiple Myeloma Bone Disease Management

Bisphosphonate Therapy Underutilized in Multiple Myeloma Bone Disease Management

By

A retrospective study evaluated timing, frequency, dosing, and other factors related to bisphosphonate therapy in patients with multiple myeloma.

Pomalidomide Plus Dexamethasone Effective in R/R Multiple Myeloma

Pomalidomide Plus Dexamethasone Effective in R/R Multiple Myeloma

By

Researchers report on their findings of a retrospective study that compared pomalidomide plus dexamethasone vs dexamethasone alone in patients with relapsed/refractory multiple myeloma.

Common Oncologic Emergencies That Occur With Multiple Myeloma

Common Oncologic Emergencies That Occur With Multiple Myeloma

By

What are the common oncologic emergencies seen in patients with MM?

Multiple Myeloma Survival Decreased With High ADAR1 RNA Expression

Multiple Myeloma Survival Decreased With High ADAR1 RNA Expression

ADAR1 knockdown reduces regeneration of high-risk multiple myeloma in patient-derived xenografts

Carfilzomib Associated With Cardiovascular Adverse Events in Multiple Myeloma

Carfilzomib Associated With Cardiovascular Adverse Events in Multiple Myeloma

By

For this meta-analysis and systematic review, investigators compiled phase 1 to 3 prospective clinical trials of carfilzomib therapy for patients with MM that had evaluable toxic effects data.

No Increased Risk for Melanoma in Patients With MM

No Increased Risk for Melanoma in Patients With MM

By

An increased prevalence of melanoma has been observed in patients with various immunocompromised conditions.

Aspirin Does Not Reduce Risk of Venous Thromboembolism in Multiple Myeloma

Aspirin Does Not Reduce Risk of Venous Thromboembolism in Multiple Myeloma

By

A retrospective study, presented at ASH 2017, determined the effectiveness of aspirin in reducing risk of VTE in patients with multiple myeloma at high risk of developing VTE.

Prolonging Survival in MM: Daratumumab vs Pomalidomide Plus Dexamethasone

Prolonging Survival in MM: Daratumumab vs Pomalidomide Plus Dexamethasone

By

A head-to-head comparison investigated whether patients with multiple myeloma achieved greater prolongation in overall survival with daratumumab monotherapy or pomalidomide plus low-dose dexamethasone.

FDA Grants Breakthrough Therapy Designation to bb2121 for Multiple Myeloma

FDA Grants Breakthrough Therapy Designation to bb2121 for Multiple Myeloma

By

Breakthrough Therapy Designation was granted for bb2121, a novel CAR T-cell therapy indicated for patients with multiple myeloma who have undergone previous treatments.

Response to Anemia Treatment Differs in Lymphoma, Multiple Myeloma

Response to Anemia Treatment Differs in Lymphoma, Multiple Myeloma

By

In this analysis, researchers measured the impact and effectiveness of supportive treatments for moderate to severe anemia in patients with lymphoma or multiple myeloma, based on patient-reported outcomes.

Flow Cytometry Assesses Minimal Residual Disease in Multiple Myeloma

Flow Cytometry Assesses Minimal Residual Disease in Multiple Myeloma

The use of flow cytometry has demonstrated usefulness in multiple myeloma recurrence assessment.

Carfilzomib Administered Once Weekly Prolongs PFS in Multiple Myeloma

Carfilzomib Administered Once Weekly Prolongs PFS in Multiple Myeloma

By

Researchers randomly assigned 478 patients with R/R MM to receive carfilzomib 70 mg/m2 once weekly plus dexamethasone or carfilzomib 27 mg/m2 twice weekly plus dexamethasone.

A Rare Case of Simultaneous Second Malignancies in Relapsed Multiple Myeloma

A Rare Case of Simultaneous Second Malignancies in Relapsed Multiple Myeloma

By

A first-reported case of simultaneous intracranial plasmacytoma and malignant pericardial effusion in a woman with relapsed multiple myeloma previously treated with chemotherapy and allogenic HSCT is described.

Daratumumab Infusion-Related Reactions Managed by Pre/Postinfusion Medications

Daratumumab Infusion-Related Reactions Managed by Pre/Postinfusion Medications

By

Patients with multiple myeloma treated with daratumumab who experience IRRs may easily be managed by administering pre-infusion and postinfusion medications, investigators reported in a presentation at ESMO 2017 Congress.

Carfilzomib Improves Overall Survival in Relapsed/Refractory Multiple Myeloma

Carfilzomib Improves Overall Survival in Relapsed/Refractory Multiple Myeloma

By

The first interim analysis of the ENDEAVOR trial reported superiority of carfilzomib in some outcomes; however, data on overall survival were not available. This second interim analysis reports on overall survival with carfilzomib for patients with relapsed/refractory multiple myeloma.

Lenalidomide After ASCT Prolongs Time to Progression in Multiple Myeloma

Lenalidomide After ASCT Prolongs Time to Progression in Multiple Myeloma

By

Time to disease progression was significantly prolonged in patients with multiple myeloma who received lenalidomide therapy after ASCT.

Emerging Combination Therapies for the Management of Multiple Myeloma: The Role of Elotuzumab

Emerging Combination Therapies for the Management of Multiple Myeloma: The Role of Elotuzumab

[Cancer Management and Research] The research examines the various combination strategies for the treatment of multiple myeloma, with a focus on the use of elotuzumab.

Induction Regimens for Untreated Multiple Myeloma Compared for ORR, OS, PFS

Induction Regimens for Untreated Multiple Myeloma Compared for ORR, OS, PFS

By

Comparison study demonstrates early response and survival benefits of VTD, VTDC, and TAD regimens in transplant-eligible patients with newly diagnosed multiple myeloma.

Ixazomib, a New PI, Offers Improved Efficacy With Acceptable Toxicity Profile for Relapsed/Refractory Multiple Myeloma

Ixazomib, a New PI, Offers Improved Efficacy With Acceptable Toxicity Profile for Relapsed/Refractory Multiple Myeloma

By

Ixazomib, a new proteasome inhibitor (PI), is a third option for the treatment of relapsed/refractory multiple myeloma (RRMM) offering the potential of improved efficacy and the convenience of oral therapy.

Type and Crossmatch Needed Before Initiating Treatment With Daratumumab

Type and Crossmatch Needed Before Initiating Treatment With Daratumumab

By

Why is a type and crossmatch needed before starting patients on treatment with daratumumab (Darzalex)?

ASCO: CAR T-Cell Therapy Promising for Multiple Myeloma

ASCO: CAR T-Cell Therapy Promising for Multiple Myeloma

Findings from trial of chimeric antigen receptor T cells targeting B-cell maturation protein demonstrated promising results.

CAR T Cells: Keeping Pace With Adverse Effects of an Emerging Therapy

CAR T Cells: Keeping Pace With Adverse Effects of an Emerging Therapy

By

The oncology nurses' role in monitoring and early recognition of the signs and symptoms of CAR T-cell toxicities is significant considering the potential severity of these adverse effects.

Combination Therapy Plus Stem-Cell Tx Ups PFS in Multiple Myeloma

Combination Therapy Plus Stem-Cell Tx Ups PFS in Multiple Myeloma

Patients with myeloma that underwent transplantation in addition to RVD had significantly longer median progression-free survival compared to the group that received RVD alone.

Novel Test For Multiple Myeloma Uses Microchip, Conventional Blood Sample

Novel Test For Multiple Myeloma Uses Microchip, Conventional Blood Sample

By

MIT team develops simple, less painful diagnostic test for multiple myeloma using microfluidic chip and conventional blood sample.

Optimal Management of Myeloma With Bortezomib

Optimal Management of Myeloma With Bortezomib

By

In this review of the role of bortezomib in the treatment of multiple myeloma, the researchers explain what nurses need to watch for in patients taking this drug.

Carfilzomib Improves OS vs Bortezomib in R/R Multiple Myeloma

Carfilzomib Improves OS vs Bortezomib in R/R Multiple Myeloma

By

Carfilzomib significantly prolonged overall survival compared with bortezomib in patients with relapsed or refractory multiple myeloma.

Earlier and Later Adult BMI Associated With Multiple Myeloma Risk

Earlier and Later Adult BMI Associated With Multiple Myeloma Risk

By

Younger and usual adult body mass index (BMI) may be linked to increased risk for developing multiple myeloma, research indicates.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs